Part of the Oncology Commons
A Phase I dose-escalation study of the BRAF inhibitor vemurafenib in combination with the MTOR inhibitor everolimus in subjects with advanced cancer, Javier Munoz Dissertations and Theses (Open Access)
PDF
Advanced Search
